Merck & CompanyvsMyriad Genetics

MRK and MYGN stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$133.63

Value $330B

-3.03%
MRK's page

MYGN

Myriad Genetics, Inc.

$5.62

Value $526M

+1.63%
MYGN's page

Merck & Company (MRK) has a market value of $330B and Myriad Genetics (MYGN) $526M. Over the last year, with dividends, MRK moved +42.7% and MYGN -15.2%. Dividend yield: MRK 2.54%, MYGN none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$330B

    MYGN$526M

    MRK is 629 times MYGN

  • Revenue, 12 months

    MRK$67.4B

    MYGN$804M

    MRK is 84 times MYGN

  • Net income, 12 months

    MRK$2.5B

    MYGN-$129M

  • Operating margin

    MRK–

    MYGN-14.3%

  • ROIC

    MRK3.9%

    MYGN-20.2%

    24.1 points apart

  • P/E

    MRK134.7

    MYGN–

  • Dividend yield

    MRK2.5%

    MYGN0.0%

    2.5 points apart

  • 5-year return

    MRK+87.4%

    MYGN-80.2%

    167.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+87.4%

MYGN-80.2%

010020020222023202420252026
Returns by period
PeriodMRKWith dividendsMYGNWith dividends
1 year since November 18, 2025+42.7%Price +38.6%-15.2%Price -15.2%
3 years since November 17, 2023+43.9%+12.9% a yearPrice +31.3%-68.6%-32.0% a yearPrice -68.6%
5 years since November 18, 2021+87.4%+13.4% a yearPrice +60.9%-80.2%-27.6% a yearPrice -80.2%
10 years since November 21, 2016+205.0%+11.8% a yearPrice +124.8%-67.2%-10.6% a yearPrice -67.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyMYGNMyriad Genetics

Valuation

MRKMYGN
Valuation
Price$133.63$5.62
Market value$330B$526M
Enterprise value (EV)$375B–
P/E134.7–
P/E, 5-year median14.8–
P/B7.42.0
EV/EBIT78.7–
Free cash flow yield4.5%–

Results and growth

MRKMYGN
Results and growth
Revenue, 12 months$67.4B$804M
Net income, 12 months$2.5B-$129M
Free cash flow, 12 months$14.7B-$34M
Earnings per share, 12 months$0.98-$1.35
Revenue growth, year on year1.3%-1.6%
Revenue growth a year, past+9.4%over 5 years+8.2%over 5 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKMYGN
Margins and returns on capital
Gross margin71.8%68.3%
Operating margin–-14.3%
Net margin3.6%-16.1%
ROIC3.9%-20.2%
ROE5.2%-39.1%

Balance sheet

MRKMYGN
Balance sheet
Cash$9.7B$107M
Total debt$53.8B–
Net debt / EBITDA5.7–
Interest cover2.4×-6.9×

Dividends and buybacks

MRKMYGN
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.5%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or MYGN

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Myriad Genetics?

By market value, Merck & Company ($330B) is about 628.7 times Myriad Genetics ($526M), at today's prices.

How did MRK and MYGN stock do over the last 10 years?

Since November 21, 2016, MRK's price moved +124.8% and MYGN's -67.2%. With dividends: MRK +205.0% (+11.8% a year), MYGN -67.2% (-10.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or MYGN?

The dividend yield at today's price is 2.54% for Merck & Company and none for Myriad Genetics. Over the last twelve months they paid $3.40 and – per share.

Which has the higher profit margins, Merck & Company or Myriad Genetics?

Over the last twelve months, the net margin was 3.6% for Merck & Company and -16.1% for Myriad Genetics, and the operating margin – and -14.3%. Revenue was $67.4B and $804M.

Which is the better investment, Merck & Company or Myriad Genetics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.